Переходьте в офлайн за допомогою програми Player FM !
Chimeric Therapeutics (ASX: CHM) achieves significant progress with latest brain cancer treatment trial (w/ Jennifer Chow)
Manage episode 380645567 series 2701497
Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the successful results of a new brain cancer (glioblastoma) treatment trial.
The phase 1A trial achieved a 55% disease control rate (DCR) in patients treated with its CLTX CAR T solution, well above historical disease control rates.
Under that trial two patients exceeded a survival period of 14 months, while three patients remained alive and in follow up.
This is in direct comparison to survival expectations of around 7 months for patients after first line therapy.
Data obtained from the dose escalation program has provided highly encouraging results, particularly with a number of participants considered very late stage cancer patients.
Chimeric is now opened enrolment for the phase 1B stage of the trials.
Articles:
https://smallcaps.com.au/chimeric-therapeutics-positive-interim-data-cltx-car-t-brain-cancer-trial/
https://smallcaps.com.au/chimeric-therapeutics-chm-0201-cell-study-treatments-acute-myeloid-leukaemia/
https://smallcaps.com.au/chimeric-therapeutics-completes-further-dosing-brain-cancer-clinical-trial/
https://smallcaps.com.au/imugene-worldwide-licence-cd19-cell-therapy-treat-relapsed-cancer-patients/
For more information on Chimeric Therapeutics:
https://smallcaps.com.au/stocks/asx-chm/
See omnystudio.com/listener for privacy information.
125 епізодів
Manage episode 380645567 series 2701497
Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the successful results of a new brain cancer (glioblastoma) treatment trial.
The phase 1A trial achieved a 55% disease control rate (DCR) in patients treated with its CLTX CAR T solution, well above historical disease control rates.
Under that trial two patients exceeded a survival period of 14 months, while three patients remained alive and in follow up.
This is in direct comparison to survival expectations of around 7 months for patients after first line therapy.
Data obtained from the dose escalation program has provided highly encouraging results, particularly with a number of participants considered very late stage cancer patients.
Chimeric is now opened enrolment for the phase 1B stage of the trials.
Articles:
https://smallcaps.com.au/chimeric-therapeutics-positive-interim-data-cltx-car-t-brain-cancer-trial/
https://smallcaps.com.au/chimeric-therapeutics-chm-0201-cell-study-treatments-acute-myeloid-leukaemia/
https://smallcaps.com.au/chimeric-therapeutics-completes-further-dosing-brain-cancer-clinical-trial/
https://smallcaps.com.au/imugene-worldwide-licence-cd19-cell-therapy-treat-relapsed-cancer-patients/
For more information on Chimeric Therapeutics:
https://smallcaps.com.au/stocks/asx-chm/
See omnystudio.com/listener for privacy information.
125 епізодів
Усі епізоди
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.